65,437 trials
Nonheme Iron Absorption
Primary: Nonheme Iron Absorption — 2.31 percentage of nonheme Iron absorbed
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -7.23; -5.02; -9.99; -8.13 score on scale — p=0.002
Urinary Catheterization
Primary: Subject's Perception Regarding Handling of Test Catheter Before Insertion — 1.71; 1.76 Score on scale
Essential Thrombocythaemia
Primary: Maximum Plasma Concentration (Cmax) of Agrylin — 2.66; 3.63 ng/ml — p=0.092
Dietary Proteins
Primary: Calcium Absorption — 18.1; 29.5; 18.0; 26 percentage of Calcium absorbed — p=0.05
Asthma
Primary: Morning (AM) Peak Expiratory Flow (PEF) Rate — -21; -22 liters per minute — p=0.99
Influenza
Primary: Number of Participants Reporting Severe Unsolicited Adverse Events — 0; 0; 0; 0 participants
Osteoarthritis, Knee
Primary: Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation — 346; 188; 121 participants
Malignant Melanoma
Primary: Overall Tumor Response — 7; 10; 6; 12 participants
Pain
Primary: AUC(0-t) — 5886; 4761 ng.h/mL
Hepatitis C, Chronic · Hepatitis C
Primary: Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey. — 6.16 Units on a scale
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Time Course of Change From Baseline in Body Mass Index (BMI) — 0.09; 0.16; 0.25; 0.27 kilograms/square meters — p=0.428
Xerostomia
Primary: Visual Analogue Scale of Subjective Dry Mouth — 5.21; 5.03 cm — p=<0.05
Alzheimer Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale Cognitive Subpart (Extended Version) (ADAS-COG+) at Week 28 — -2.348; -1.711; -1.246 points on a scale…
Diabetic Neuropathies
Primary: Change From Baseline to 12 Week Endpoint in Brief Pain Inventory 24-hour Average Pain Score — -2.69; -2.31 units on a scale — p=0.617